Accumulate Indoco Remedies; target of Rs 320: Prabhudas Lilladher

Accumulate

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

We cut our FY25/FY26 EPS by ~37%/14% to factor in low margins and lower sales across key markets. Our numbers do factor in margin recovery with reduction in remediation cost from H2FY25. Indoco Remedies’ (INDR) Q1FY25 EBITDA was sharply below our estimates led by muted US sales and lower GMs. The recent OAI to its Goa unit-2 is negative and will restrict growth in US sales in FY25. We expect 30% PAT CAGR over FY24-26E given low base. At CMP, stock is trading at 20.5x FY26E EPS.

We maintain our Accumulate with revised TP of Rs320 valuing at 20x (18x earlier) FY26E EPS. Timely resolution of Goa facility unit-2 is a key for re-rating.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.